Life Sciences Discovery Fund
Life sciences, Biotechnology, Venture capital / Investment
Facts
- HQ
- Washington
- Sectors
- Life sciences, Biotechnology, Venture capital / Investment
Recent coverage
Front-page news, podcasts and videos about Life Sciences…
Athira Pharma raises $204M in IPO at $17/share, values company at ~$670M to advance Alzheimer’s drug NDX-1017
Seattle biotech Athira Pharma raised $204 million by selling 12 million shares in a Nasdaq IPO at $17 per share, valuing the company at about $670 million as it advances its lead Alzheimer’s therapeutic NDX-1017 into late-stage development.
Athira Pharma raises $85M Series B to push NDX-1017 toward FDA approval for Alzheimer’s, Parkinson’s and ALS
Seattle biotech Athira Pharma raised $85 million in a Series B round to advance NDX-1017, a regenerative therapy aimed at halting or reversing nerve damage in Alzheimer’s, Parkinson’s and ALS, with preliminary trial results reported as positive and potential market availability in 2–3 years.
